Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Medtronic
AstraZeneca
Moodys
McKinsey
Merck
Dow

Last Updated: October 21, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Pictilisib

See Plans and Pricing

« Back to Dashboard

Drug Development Status for Pictilisib: Patents, clinical trial progress, indications

Pictilisib is an investigational drug.

There have been 4 clinical trials for Pictilisib. The most recent clinical trial was a Phase 1 trial, which was initiated on March 1st 2013.

The most common disease conditions in clinical trials are Breast Neoplasms, Gliosarcoma, and Glioblastoma. The leading clinical trial sponsors are Genentech, Inc., ECCO - the European CanCer Organisation, and Department of Experimental Clinical Oncology, Aarhus University Hospital.

There are one hundred US patents protecting this investigational drug and nine hundred and fifty-one international patents.

Recent Clinical Trials for Pictilisib
TitleSponsorPhase
PIPA: Combination of PI3 Kinase Inhibitors and PAlbociclibInstitute of Cancer Research, United KingdomPhase 1
PIPA: Combination of PI3 Kinase Inhibitors and PAlbociclibPfizerPhase 1
PIPA: Combination of PI3 Kinase Inhibitors and PAlbociclibRoche Pharma AGPhase 1

See all Pictilisib clinical trials

Clinical Trial Summary for Pictilisib

Top disease conditions for Pictilisib
Top clinical trial sponsors for Pictilisib

See all Pictilisib clinical trials

US Patents for Pictilisib

Glossary
Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Pictilisib   Start Trial In vitro production of foregut stem cells Cambridge Enterprise Limited (GB)   Start Trial
Pictilisib   Start Trial Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines Signal Pharmaceuticals, LLC (San Diego, CA)   Start Trial
Pictilisib   Start Trial Methods of treating PR-positive, luminal A breast cancer with PI3K inhibitor, pictilisib Genentech, Inc. (South San Francisco, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Subscribe to access the full database, or Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
McKinsey
Moodys
AstraZeneca
Boehringer Ingelheim
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
Copyright 2002-2019 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
Major Patent Expirations 2019 - 2020
 NCE-1 Generic Application Dates 2019 - 2020
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2019, www.DrugPatentWatch.com.

Links

Follow DrugPatentWatch:

DrugPatentWatch reviews